- 米国企業
- BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.BBIO
時価総額
$52.3億
PER
2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
License Revenue | 14 | 8 | 66 | - |
License and services revenue | - | - | - | 76 |
Product Sales | - | - | 4 | 2 |
Total revenue | 41 | 8 | 70 | 78 |
Cost of license revenue and products sold | - | - | - | 3 |
Research and development | 210 | 337 | 451 | 399 |
Selling, general and administrative | - | - | 192 | 143 |
Restructuring Charges | - | - | - | 44 |
Total operating costs and expenses | - | - | 646 | 590 |
Loss from operations | -266 | -474 | -577 | -512 |
Interest income | 9 | 4 | 1 | 8 |
Interest expense | 9 | 37 | 47 | 80 |
Gain from sale of priority review voucher, net | - | - | - | 108 |
Other income (expense), net | - | 2 | 36 | -7 |
Total other income (expense), net | -22 | -31 | -10 | 28 |
Total loss before income taxes | -289 | -505 | -586 | -485 |
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | -28 | -57 | -24 | -3 |
Net loss attributable to common stockholders of BridgeBio | -261 | -449 | -563 | -481 |
Earnings Per Share, Basic | - | - | - | -3.26 |
Earnings Per Share, Diluted | - | - | - | -3.26 |